Top Insights
Health
globalreutersDecember 3, 20241 Mins read
Takeda Pays $200M for Keros Therapeutics Drug With Potential in Blood Cancers and Beyond
globalreutersDecember 3, 20241 Mins read 
Keros Therapeutics will present Phase 2 data for the drug, elritercept, at the annual meeting of the American Society of Hematology. Meanwhile, the Takeda deal enables Keros to focus on two wholly owned assets, one of which could compete with a Merck drug approved earlier this year.
The post Takeda Pays $200M for Keros Therapeutics Drug With Potential in Blood Cancers and Beyond appeared first on MedCity News.
Recent Posts
Categories
Related Articles
Video: Battle of the Bulge – Wegovy vs. Zepbound
The GLP-1 battle heats up with new preliminary data from Eli Lilly...
Bowel Cancer vs Colon Cancer: A Guide to Awareness and Prevention
Bowel cancer vs colon cancer are two common types of cancer that...
Leave a comment